论文部分内容阅读
目的:探讨桂枝茯苓丸对子宫内膜异位症(EMS)大鼠止疼痛的作用机制及对基质金属蛋白酶表达的影响。方法:复制大鼠模型,分为模型组,芬必得组(0.054 g·kg-1),丹那唑组(0.036 g·kg-1),桂枝茯苓丸低、高剂量组(含生药0.256,1.024 g·kg-1),连续ig给药4周,放免法测定大鼠血浆中6-酮前列腺素F1α(6-keto-PGF1α),β-内啡肽(β-EP),血栓素B2(TXB2),剥取大鼠异位内膜组织,测定体积,并检测基质金属蛋白酶-2(MMP-2),基质金属蛋白酶-9(MMP-9)在异位内膜的表达。结果:桂枝茯苓丸各组异位内膜体积明显减小(P<0.01);桂枝茯苓丸各剂量组均能升高大鼠血浆6-keto-PGF1 a,β-EP水平,降低TXB2水平(P<0.01);桂枝茯苓丸各剂量组MMP-2及MMP-9表达阳性强度均降低(P<0.05,P<0.01)。结论:桂枝茯苓丸能抑制异位内膜的生长,其作用机制可能与抑制内膜组织中MMP-2及MMP-9表达有关;桂枝茯苓丸止痛机制可能是通过平衡前列腺素水平,缓解子宫平滑肌痉挛,升高内啡肽实现的。
Objective: To investigate the mechanism of action of Guizhi Fuling Capsule on pain in rats with endometriosis (EMS) and its effect on expression of matrix metalloproteinase (MMP). METHODS: Rat models were divided into three groups: model group, Fenbid group (0.054 g · kg -1), Danazol group (0.036 g · kg -1), Guizhifuling capsule low and high dose group 1.024 g · kg-1) for 4 weeks. The levels of 6-keto-PGF1α, β-EP, (TXB2). The ectopic endometrial tissues of rats were stripped and their volume was measured. The expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in ectopic endometrium was detected. Results: The volume of ectopic endometrium of Guizhi Fuling capsule decreased significantly (P <0.01), and the levels of 6-keto-PGF1 a and β-EP of rats in each dose group of Guizhi Fuling capsule increased and the level of TXB2 decreased (P <0.01). The positive expression of MMP-2 and MMP-9 in each group of Guizhi Fuling Capsule decreased (P <0.05, P <0.01). Conclusion: Guizhi Fuling pill can inhibit the growth of ectopic endometrium, and its mechanism may be related to the inhibition of the expression of MMP-2 and MMP-9 in endometrial tissue. The mechanism of pain-relieving of Guizhi Fuling pill may be through the balance of prostaglandin level, Uterine smooth muscle spasm, elevated endorphin achieved.